Tempus AI
TEM on Nasdaq. Tempus sells genomic tests and health data to doctors and drug companies. Market value $11.0bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Technology stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-2098.45 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$71.98 a share, 77% above its 1-year low
Over the past year the price has ranged from $40.77 to $104.32.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | ||
| Revenue | $693m | $1.3bn |
| Operating margin | ||
| Operating margin | -99.7% | -19.9% |
| Debt to equity | ||
| Debt to equity | n/a | n/a |
| Shares outstanding | ||
| Shares outstanding | 0.00bn | 0.00bn |
Health checks
- Free cash flow positive0 of 2 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 45% more shares since 2024
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $382 million last quarter, up 22% on a year ago.
- Profit: $6 million, after a loss of $43 million a year ago.
- It loses 20 cents on each $1 of sales, compared with 25 cents a year earlier.
- Over the past 12 months it spent $263 million more cash than it brought in, compared with $70 million a year earlier.
- 5% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $181m |
| December 2024 | $201m |
| March 2025 | $256m |
| June 2025 | $315m |
| September 2025 | $334m |
| December 2025 | $367m |
| March 2026 | $348m |
| June 2026 | $382m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$76m |
| December 2024 | -$13m |
| March 2025 | -$68m |
| June 2025 | -$43m |
| September 2025 | -$80m |
| December 2025 | -$54m |
| March 2026 | -$126m |
| June 2026 | $6m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 24 February 2026
- Next quarterly (estimated, 10-Q)
- 29 October 2026
Who owns it
3 long-term investors we follow own it, unchanged from 3 last quarter. 488 funds in all.
- H&H International InvestmentDuan Yongping
- Value
- $1m
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Patient Capital ManagementSamantha McLemore | $23m | 0.8% | Cut |
| Gotham Asset ManagementJoel Greenblatt | $3m | <0.1% | Added |
| H&H International InvestmentDuan Yongping | $1m | <0.1% |
Largest holders overall
- ARK Investment Management$581mAdded
- BlackRock$480mCut
- Baillie Gifford$474mCut
- Softbank Group$313m
- JPMorgan Chase$291m
- Vanguard Capital Management$289m
- Vanguard Portfolio Management$285mAdded
- Sumitomo Mitsui Trust Group$237mCut
- Amova Asset Management Americas$237mCut
- Goldman Sachs Group$218mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Eric Paul LefkofskyPassive investorat least 24.0%−1.9 pts(filed with 3 related holders)Since 31 December 2025
- Bradley A. KeywellPassive investorat least 7.6%(filed with 1 related holder)Since 17 January 2025
- ARK Investment Management LLCPassive investorat least 5.4%(filed with 1 related holder)Since 28 February 2026
- BAILLIE GIFFORD & COPassive investor5.0%−0.8 ptsSince 31 March 2026
- Red Sky Ventures LLCPassive investorat least 4.7%−1.0 pts(filed with 1 related holder)Since 30 September 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Eric Paul Lefkofsky Passive investor | at least 24.0%−1.9 pts (filed with 3 related holders) | 31 December 2025 | |
Bradley A. Keywell Passive investor | at least 7.6% (filed with 1 related holder) | 17 January 2025 | |
ARK Investment Management LLC Passive investor | at least 5.4% (filed with 1 related holder) | 28 February 2026 | |
BAILLIE GIFFORD & CO Passive investor | 5.0%−0.8 pts | 31 March 2026 | |
Red Sky Ventures LLC Passive investor | at least 4.7%−1.0 pts (filed with 1 related holder) | 30 September 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 11 sold $221m, $206m of it under preset trading plans.
- Schoenherr Thomas EdwardCEO, DiagnosticsSoldunder a preset trading plan
- Date
- 25 September 2026
- Shares
- 10,281
- Price
- $85.00
- Value
- $873,885
- LEFKOFSKY ERIC PCEO and Chairman, DirectorSoldunder a preset trading plan
- Date
- 22 September 2026
- Shares
- 250,000
- Price
- $77.47
- Value
- $19m
- Polovin AndrewEVP, Chief Legal OfficerSoldunder a preset trading plan
- Date
- 17 September 2026
- Shares
- 2,951
- Price
- $75.00
- Value
- $221,325
- Bartolucci Ryan MChief Accounting OfficerSoldunder a preset trading plan
- Date
- 17 September 2026
- Shares
- 7,062
- Price
- $75.00
- Value
- $529,650
- LEFKOFSKY ERIC PCEO and Chairman, DirectorSoldunder a preset trading plan
- Date
- 17 September 2026
- Shares
- 200,000
- Price
- $80.57
- Value
- $16m
- Fukushima RyanCEO, DataSoldunder a preset trading plan
- Date
- 16 September 2026
- Shares
- 700
- Price
- $70.00
- Value
- $49,000
- Fukushima RyanCEO, DataSoldunder a preset trading plan
- Date
- 1 September 2026
- Shares
- 30,846
- Price
- $62.71
- Value
- $2m
- Doudna Jennifer ADirectorSoldunder a preset trading plan
- Date
- 1 September 2026
- Shares
- 676
- Price
- $65.55
- Value
- $44,312
- Epstein David RDirectorSoldunder a preset trading plan
- Date
- 1 September 2026
- Shares
- 250
- Price
- $65.55
- Value
- $16,388
- West NadjaDirectorSoldunder a preset trading plan
- Date
- 28 August 2026
- Shares
- 3,000
- Price
- $69.00
- Value
- $207,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 25 September 2026 | Schoenherr Thomas Edward CEO, Diagnostics | Sold under a preset trading plan | 10,281 | $85.00 | $873,885 |
| 22 September 2026 | LEFKOFSKY ERIC P CEO and Chairman, Director | Sold under a preset trading plan | 250,000 | $77.47 | $19m |
| 17 September 2026 | Polovin Andrew EVP, Chief Legal Officer | Sold under a preset trading plan | 2,951 | $75.00 | $221,325 |
| 17 September 2026 | Bartolucci Ryan M Chief Accounting Officer | Sold under a preset trading plan | 7,062 | $75.00 | $529,650 |
| 17 September 2026 | LEFKOFSKY ERIC P CEO and Chairman, Director | Sold under a preset trading plan | 200,000 | $80.57 | $16m |
| 16 September 2026 | Fukushima Ryan CEO, Data | Sold under a preset trading plan | 700 | $70.00 | $49,000 |
| 1 September 2026 | Fukushima Ryan CEO, Data | Sold under a preset trading plan | 30,846 | $62.71 | $2m |
| 1 September 2026 | Doudna Jennifer A Director | Sold under a preset trading plan | 676 | $65.55 | $44,312 |
| 1 September 2026 | Epstein David R Director | Sold under a preset trading plan | 250 | $65.55 | $16,388 |
| 28 August 2026 | West Nadja Director | Sold under a preset trading plan | 3,000 | $69.00 | $207,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.